康辰药业:KC1086联合氟维司群治疗乳腺癌获临床试验通知书

同花顺
Oct 16

10月16日,康辰药业(603590)(603590.SH)公告称,公司收到国家药监局核准签发的临床试验通知书,同意KC1086片联合氟维司群在HR+/HER2-局部晚期或转移性乳腺癌中开展临床研究。KC1086为公司自主研发的化学药品1类创新药(886015),为强效KAT6/7双靶点小分子抑制剂,已获美国FDA新药临床研究默许,是全球首个进入临床开发阶段的KAT6/7小分子抑制剂。公司拟开展Ⅱ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10